Oncolytics' Phase III Borrows Adaptive Design in SPA Trial
Oncolytics Biotech Inc. reached agreement with the FDA on the design of a Phase III trial of Reolysin in head and neck cancer, marking the first such agreement for an intravenously administered oncolytic virus. (BioWorld Today)